Trifluridine - Tipiracil

Trifluridin/Tipiracil (Lonsurf®), which received FDA approval on 22 September 2015, is administered to patients who previously used fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy drugs and drugs preventing new blood vessel formation, with disease spread to distant tissues (metastatic), and colorectal cancer (large bowel cancer) . Lonsurf contains two separate molecules together and can thus be more effective. New blood vessels need to form both for the cancer cell to obtain more nourishment and for it to spread to distant tissues.
Tipiracil inhibits the functioning of thymidine phosphorylase, involved in new blood vessel formation, while Trifluridin binds directly to the cancer cell’s DNA and prevents cell division. Anemia, fatigue, nausea, loss of appetite and decreased blood cells are its most common side effects.
Was this article helpful?
Your feedback helps us improve our content.



Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.